Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIONEER PSMA: ADT effect on PSMA-PET sensitivity
NCT07069465Phase 1Completed
- Sponsor
- Urology Clinics of North Texas
- Start
- Jun 2024
- Primary completion
- Nov 2024
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 1, open-label trial of tissue-plasminogen activator in prostate cancer (PCa) (2 cohorts), sponsored by Urology Clinics of North Texas. Primary endpoints: Mean change in maximum standardized uptake value (SUVmax) per lesion, New lesions not identified pre-treatment are detectable after ADT and 2 more. Started Jun 2024; status: completed.
02
Drugs
tissue-plasminogen activator
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07069465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07069465.